Pharmalucence receives FDA notification that Sulfur Colloid Injection (SCI) has been granted Orphan Drug designation status and seven years of market exclusivity for its use in lymph node localization in melanoma patients.
Pharmalucence receives FDA notification that Sulfur Colloid Injection (SCI) has been granted Orphan Drug designation status and seven years of market exclusivity for its use in lymph node localization in melanoma patients.